Killing me softly-future challenges in apoptosis research

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 3746-3767

  Westhoff, Mike Andrew ^a   Brühl, Oliver ^b   Nonnenmacher, Lisa ^a   Karpel Massler, Georg ^a   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Laboratorio Analisi Sicilia Catania   (Italy)

Author keywords

Apoptosis; Cancer therapy; Chronification; Combination therapy; Microenvironment

Indexed keywords

BORTEZOMIB; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; HEAT SHOCK PROTEIN 70; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOXANTRONE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; RAF PROTEIN; RITUXIMAB; TIPIFARNIB; TREOSULFAN; VINCRISTINE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CANCER RESEARCH; CANCER THERAPY; CELL ADHESION; CELL CYCLE; CELL INTERACTION; ENVIRONMENTAL CHANGE; GLIOBLASTOMA; HISTIOCYTIC LYMPHOMA; HUMAN; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; LYMPHATIC LEUKEMIA; MULTIPLE MYELOMA; MYELOID LEUKEMIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVIEW; WNT SIGNALING PATHWAY; BIOLOGICAL MODEL; CHEMORADIOTHERAPY; DRUG EFFECTS; METABOLISM; NEOPLASMS; RADIATION RESPONSE; SIGNAL TRANSDUCTION;

APOPTOSIS; CHEMORADIOTHERAPY; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84895421055     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15033746     Document Type: Review

References (110)

1. Kaczmarek, A.; Vandenabeele, P.; Krysko, D.V. Necroptosis: The release of damage-associated molecular patterns and its physiological relevance. Immunity 2013, 38, 209-223.
2. Levine, B.; Yuan, J. Autophagy in cell death: An innocent convict? J. Clin. Investig. 2005, 115, 2679-2688.
3. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495-516.
4. Kerr, J.F.; Wyllie, A.H.; Currie, A.R. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26, 239-257.
5. Maghsoudi, N.; Zakeri, Z.; Lockshin, R.A. Programmed cell death and apoptosis-Where it came from and where it is going: From elie metchnikoff to the control of caspases. Exp. Oncol. 2012, 34, 146-152.
6. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674.
7. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
8. Sutherland, R.M.; Durand, R.E. Radiosensitization by nifuroxime of the hypoxic cells in an in vitro tumour model. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 1972, 22, 613-618.
9. Durand, R.E.; Sutherland, R.M. Radiation-resistant tumor cells may be more sensitive in vitro. Cancer Res. 1972, 32, 2587-2588.
10. Sutherland, R.M.; Durand, R.E. Cell contact as a possible contribution to radiation resistance of some tumours. Br. J. Radiol. 1972, 45, 788-789.
11. Chiarugi, P.; Giannoni, E. Anoikis: A necessary death program for anchorage-dependent cells. Biochem. Pharmacol. 2008, 76, 1352-1364.
12. Damiano, J.S.; Hazlehurst, L.A.; Dalton, W.S. Cell adhesion-mediated drug resistance (cam-dr) protects the k562 chronic myelogenous leukemia cell line from apoptosis induced by bcr/abl inhibition, cytotoxic drugs, and gamma-irradiation. Leukemia 2001, 15, 1232-1239.
13. Schmidmaier, R.; Baumann, P.; Simsek, M.; Dayyani, F.; Emmerich, B.; Meinhardt, G. The hmg-coa reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of rho protein and activation of rho kinase. Blood 2004, 104, 1825-1832.
14. Hazlehurst, L.A.; Argilagos, R.F.; Emmons, M.; Boulware, D.; Beam, C.A.; Sullivan, D.M.; Dalton, W.S. Cell adhesion to fibronectin (cam-dr) influences acquired mitoxantrone resistance in u937 cells. Cancer Res. 2006, 66, 2338-2345.
15. Yanamandra, N.; Colaco, N.M.; Parquet, N.A.; Buzzeo, R.W.; Boulware, D.; Wright, G.; Perez, L.E.; Dalton, W.S.; Beaupre, D.M. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia. Clin. Cancer Res. 2006, 12, 591-599.
16. Matsunaga, T.; Fukai, F.; Miura, S.; Nakane, Y.; Owaki, T.; Kodama, H.; Tanaka, M.; Nagaya, T.; Takimoto, R.; Takayama, T.; et al. Combination therapy of an anticancer drug with the fniii14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008, 22, 353-360.
17. Nimmanapalli, R.; Gerbino, E.; Dalton, W.S.; Gandhi, V.; Alsina, M. Hsp70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br. J. Haematol. 2008, 142, 551-561.
18. Wang, X.; Wang, C.; Qin, Y.W.; Yan, S.K.; Gao, Y.R. The association of up-regulation of x-linked inhibitor of apoptosis protein with cell adhesion-mediated drug resistance in u937 cells. Hematol. Oncol. 2008, 26, 21-26.
19. Noborio-Hatano, K.; Kikuchi, J.; Takatoku, M.; Shimizu, R.; Wada, T.; Ueda, M.; Nobuyoshi, M.; Oh, I.; Sato, K.; Suzuki, T.; et al. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of vla-4 expression in multiple myeloma. Oncogene 2009, 28, 231-242.
20. Bourogaa, E.; Bertrand, J.; Despeaux, M.; Jarraya, R.; Fabre, N.; Payrastre, L.; Demur, C.; Fournie, J.J.; Damak, M.; Feki, A.E.; et al. Hammada scoparia flavonoids and rutin kill adherent and chemoresistant leukemic cells. Leuk. Res. 2011, 35, 1093-1101.
21. Mraz, M.; Zent, C.S.; Church, A.K.; Jelinek, D.F.; Wu, X.; Pospisilova, S.; Ansell, S.M.; Novak, A.J.; Kay, N.E.; Witzig, T.E.; et al. Bone marrow stromal cells protect lymphoma b-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (vla-4) with natalizumab can overcome this resistance. Br. J. Haematol. 2011, 155, 53-64.
22. Kiziltepe, T.; Ashley, J.D.; Stefanick, J.F.; Qi, Y.M.; Alves, N.J.; Handlogten, M.W.; Suckow, M.A.; Navari, R.M.; Bilgicer, B. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2012, 2, e64.
23. Hazlehurst, L.A.; Valkov, N.; Wisner, L.; Storey, J.A.; Boulware, D.; Sullivan, D.M.; Dalton, W.S. Reduction in drug-induced DNA double-strand breaks associated with β1 integrin-mediated adhesion correlates with drug resistance in u937 cells. Blood 2001, 98, 1897-1903.
24. Zhu, B.; Zhao, L.; Zhu, L.; Wang, H.; Sha, Y.; Yao, J.; Li, Z.; You, Q.; Guo, Q. Oroxylin a reverses cam-dr of hepg2 cells by suppressing integrinβ1 and its related pathway. Toxicol. Appl. Pharmacol. 2012, 259, 387-394.
25. Bjorklund, C.C.; Baladandayuthapani, V.; Lin, H.Y.; Jones, R.J.; Kuiatse, I.; Wang, H.; Yang, J.; Shah, J.J.; Thomas, S.K.; Wang, M.; et al. Evidence of a role for cd44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: Therapeutic implications. Leukemia 2014, 28, 373-383.
26. Fei, M.; Hang, Q.; Hou, S.; Ruan, C. Cell adhesion to fibronectin down-regulates the expression of spy1 and contributes to drug resistance in multiple myeloma cells. Int. J. Hematol. 2013, 98, 446-455.
27. Damiano, J.S.; Cress, A.E.; Hazlehurst, L.A.; Shtil, A.A.; Dalton, W.S. Cell adhesion mediated drug resistance (cam-dr): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93, 1658-1667.
28. Westhoff, M.A.; Zhou, S.; Bachem, M.G.; Debatin, K.M.; Fulda, S. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 2008, 27, 5169-5181.
29. Shain, K.H.; Landowski, T.H.; Dalton, W.S. Adhesion-mediated intracellular redistribution of c-fas-associated death domain-like il-1-converting enzyme-like inhibitory protein-long confers resistance to cd95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol. 2002, 168, 2544-2553.
30. Taylor, S.T.; Hickman, J.A.; Dive, C. Epigenetic determinants of resistance to etoposide regulation of bcl-x(l) and bax by tumor microenvironmental factors. J. Natl. Cancer Inst. 2000, 92, 18-23.
31. Lwin, T.; Hazlehurst, L.A.; Li, Z.; Dessureault, S.; Sotomayor, E.; Moscinski, L.C.; Dalton, W.S.; Tao, J. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-κB (relb/p52) in non-hodgkin's lymphoma cells. Leukemia 2007, 21, 1521-1531.
32. Fortney, J.E.; Zhao, W.; Wenger, S.L.; Gibson, L.F. Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk. Res. 2001, 25, 901-907.
33. Niedermeier, M.; Hennessy, B.T.; Knight, Z.A.; Henneberg, M.; Hu, J.; Kurtova, A.V.; Wierda, W.G.; Keating, M.J.; Shokat, K.M.; Burger, J.A. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit cxcr4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: A novel therapeutic approach. Blood 2009, 113, 5549-5557.
34. Aoudjit, F.; Vuori, K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20, 4995-5004.
35. Sethi, T.; Rintoul, R.C.; Moore, S.M.; MacKinnon, A.C.; Salter, D.; Choo, C.; Chilvers, E.R.; Dransfield, I.; Donnelly, S.C.; Strieter, R.; et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5, 662-668.
36. Uhm, J.H.; Dooley, N.P.; Kyritsis, A.P.; Rao, J.S.; Gladson, C.L. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. Clin. Cancer Res. 1999, 5, 1587-1594.
37. Wang, L.; Li, Z.; Wang, C.; Yang, Y.; Sun, L.; Yao, W.; Cai, X.; Wu, G.; Zhou, F.; Zha, X. E-cadherin decreased human breast cancer cells sensitivity to staurosporine by up-regulating bcl-2 expression. Arch. Biochem. Biophys. 2009, 481, 116-122.
38. Cordes, N.; Meineke, V. Cell adhesion-mediated radioresistance (cam-rr). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther. Onkol. 2003, 179, 337-344.
39. Sandfort, V.; Koch, U.; Cordes, N. Cell adhesion-mediated radioresistance revisited. Int. J. Radiat. Biol. 2007, 83, 727-732.
40. Westhoff, M.A.; Fulda, S. Adhesion-mediated apoptosis resistance in cancer. Drug Resist. Updat. 2009, 12, 127-136.
41. Dolberg, D.S.; Bissell, M.J. Inability of rous sarcoma virus to cause sarcomas in the avian embryo. Nature 1984, 309, 552-556.
42. Bissell, M.J.; Radisky, D. Putting tumours in context. Nat. Rev. Cancer 2001, 1, 46-54.
43. Hoelzinger, D.B.; Demuth, T.; Berens, M.E. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J. Natl. Cancer Inst. 2007, 99, 1583-1593.
44. Pullan, S.; Wilson, J.; Metcalfe, A.; Edwards, G.M.; Goberdhan, N.; Tilly, J.; Hickman, J.A.; Dive, C.; Streuli, C.H. Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J. Cell. Sci. 1996, 109, 631-642.
45. Chidgey, M.; Dawson, C. Desmosomes: A role in cancer? Br. J. Cancer 2007, 96, 1783-1787.
46. Morin, P.J. Claudin proteins in human cancer: Promising new targets for diagnosis and therapy. Cancer Res. 2005, 65, 9603-9606.
47. Langlois, M.J.; Bergeron, S.; Bernatchez, G.; Boudreau, F.; Saucier, C.; Perreault, N.; Carrier, J.C.; Rivard, N. The pten phosphatase controls intestinal epithelial cell polarity and barrier function: Role in colorectal cancer progression. PLoS One 2010, 5, e15742.
48. Mendoza, M.C.; Er, E.E.; Blenis, J. The ras-erk and pi3k-mtor pathways: Cross-talk and compensation. Trends Biochem. Sci. 2011, 36, 320-328.
49. Westhoff, M.A.; Zhou, S.; Nonnenmacher, L.; Karpel-Massler, G.; Jennewein, C.; Schneider, M.; Halatsch, M.E.; Carragher, N.O.; Baumann, B.; Krause, A.; et al. Inhibition of NF-κB signaling ablates the invasive phenotype of glioblastoma. Mol. Cancer Res. 2013, 11, 1611-1623.
50. Paolillo, M.; Russo, M.A.; Serra, M.; Colombo, L.; Schinelli, S. Small molecule integrin antagonists in cancer therapy. Mini Rev. Med. Chem. 2009, 9, 1439-1446.
51. Mas-Moruno, C.; Rechenmacher, F.; Kessler, H. Cilengitide: The first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 2010, 10, 753-768.
52. Miller, D.H.; Weber, T.; Grove, R.; Wardell, C.; Horrigan, J.; Graff, O.; Atkinson, G.; Dua, P.; Yousry, T.; Macmanus, D.; et al. Firategrast for relapsing remitting multiple sclerosis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2012, 11, 131-139.
53. Tomlinson, I.P.; Novelli, M.R.; Bodmer, W.F. The mutation rate and cancer. Proc. Natl. Acad. Sci. USA 1996, 93, 14800-14803.
54. Hu, M.; Polyak, K. Microenvironmental regulation of cancer development. Curr. Opin. Genet. Dev. 2008, 18, 27-34.
55. Kaplan, R.N.; Rafii, S.; Lyden, D. Preparing the "Soil": The premetastatic niche. Cancer Res. 2006, 66, 11089-11093.
56. Sceneay, J.; Smyth, M.J.; Moller, A. The pre-metastatic niche: Finding common ground. Cancer Metastasis Rev. 2013, 32, 449-464.
57. Schultz, G.S.; Davidson, J.M.; Kirsner, R.S.; Bornstein, P.; Herman, I.M. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen. 2011, 19, 134-148.
58. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989, 8, 98-101.
59. An, X.; Tiwari, A.K.; Sun, Y.; Ding, P.R.; Ashby, C.R., Jr.; Chen, Z.S. Bcr-abl tyrosine kinase inhibitors in the treatment of philadelphia chromosome positive chronic myeloid leukemia: A review. Leuk. Res. 2010, 34, 1255-1268.
60. Gately, S.; Kerbel, R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 2001, 7, 427-436.
61. Kerbel, R.; Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2002, 2, 727-739.
62. Yuan, T.L.; Cantley, L.C. Pi3k pathway alterations in cancer: Variations on a theme. Oncogene 2008, 27, 5497-5510.
63. Cassinelli, G.; Zuco, V.; Gatti, L.; Lanzi, C.; Zaffaroni, N.; Colombo, D.; Perego, P. Targeting the akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr. Med. Chem. 2013, 20, 1923-1945.
64. Franke, T.F. Pi3k/akt: Getting it right matters. Oncogene 2008, 27, 6473-6488.
65. Hemmings, B.A.; Restuccia, D.F. Pi3k-pkb/akt pathway. Cold Spring Harb. Perspect. Biol. 2012, 4, a011189.
66. Chalhoub, N.; Baker, S.J. Pten and the pi3-kinase pathway in cancer. Annu. Rev. Pathol. 2009, 4, 127-150.
67. Brana, I.; Siu, L.L. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med. 2012, 10, 161.
68. Yin, Y.; Shen, W.H. Pten: A new guardian of the genome. Oncogene 2008, 27, 5443-5453.
69. Burris, H.A., 3rd, Overcoming acquired resistance to anticancer therapy: Focus on the pi3k/akt/mtor pathway. Cancer Chemother. Pharmacol. 2013, 71, 829-842.
70. Figlin, R.A.; Kaufmann, I.; Brechbiel, J. Targeting pi3k and mtorc2 in metastatic renal cell carcinoma: New strategies for overcoming resistance to vegfr and mtorc1 inhibitors. Int. J. Cancer 2013, 133, 788-796.
71. Fulda, S. The pi3k/akt/mtor pathway as therapeutic target in neuroblastoma. Curr. Cancer Drug Targets 2009, 9, 729-737.
72. Wolin, E.M. Pi3k/akt/mtor pathway inhibitors in the therapy of pancreatic neuroendocrine tumors. Cancer Lett. 2013, 335, 1-8.
73. Okumura, N.; Yoshida, H.; Kitagishi, Y.; Murakami, M.; Nishimura, Y.; Matsuda, S. Pi3k/akt/pten signaling as a molecular target in leukemia angiogenesis. Adv. Hematol. 2012, 2012, 843085.
74. Wen, P.Y.; Lee, E.Q.; Reardon, D.A.; Ligon, K.L.; Alfred Yung, W.K. Current clinical development of pi3k pathway inhibitors in glioblastoma. Neuro Oncol. 2012, 14, 819-829.
75. Lee, M.J.; Ye, A.S.; Gardino, A.K.; Heijink, A.M.; Sorger, P.K.; MacBeath, G.; Yaffe, M.B. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149, 780-794.
76. Westhoff, M.A.; Faham, N.; Marx, D.; Nonnenmacher, L.; Jennewein, C.; Enzenmüller, S.; Gonzalez, P.; Fulda, S.; Debatin, K.M. Sequential dosing in chemosensitization: Targeting the PI3K/Akt/mTOR pathway in neuroblastoma. PLoS One 2013, 8, e83128.
77. Hoelzinger, D.B.; Mariani, L.; Weis, J.; Woyke, T.; Berens, T.J.; McDonough, W.S.; Sloan, A.; Coons, S.W.; Berens, M.E. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia 2005, 7, 7-16.
78. Mullighan, C.G.; Phillips, L.A.; Su, X.; Ma, J.; Miller, C.B.; Shurtleff, S.A.; Downing, J.R. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008, 322, 1377-1380.
79. Denison, T.A.; Bae, Y.H. Tumor heterogeneity and its implication for drug delivery. J. Control. Release 2012, 164, 187-191.
80. Huang, S. Genetic and non-genetic instability in tumor progression: Link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer Metastasis Rev. 2013, 32, 423-448.
81. Brock, A.; Chang, H.; Huang, S. Non-genetic heterogeneity-A mutation-independent driving force for the somatic evolution of tumours. Nat. Rev. Genet. 2009, 10, 336-342.
82. Foo, J.; Leder, K.; Mumenthaler, S.M. Cancer as a moving target: Understanding the composition and rebound growth kinetics of recurrent tumors. Evol. Appl. 2013, 6, 54-69.
83. Gatenby, R.A.; Silva, A.S.; Gillies, R.J.; Frieden, B.R. Adaptive therapy. Cancer Res. 2009, 69, 4894-4903.
84. Gatenby, R.A.; Brown, J.; Vincent, T. Lessons from applied ecology: Cancer control using an evolutionary double bind. Cancer Res. 2009, 69, 7499-7502.
85. Durrett, R. Population genetics of neutral mutations in exponentially growing cancer cell populations. Ann. Appl. Probab. 2013, 23, 230-250.
86. Nonnenmacher, L.; Westhoff, M.A.; Fulda, S.; Karpel-Massler, G.; Halatsch, M.; Engelke, J.; Simmet, T.; Gorbacioglu, S.; Debatin, K.M. RIST: A potent new combination therapy for glioblastoma. Clin. Cancer Res. 2014, to be submitted.
87. Zhou, J.; Bi, C.; Janakakumara, J.V.; Liu, S.C.; Chng, W.J.; Tay, K.G.; Poon, L.F.; Xie, Z.; Palaniyandi, S.; Yu, H.; et al. Enhanced activation of stat pathways and overexpression of survivin confer resistance to flt3 inhibitors and could be therapeutic targets in aml. Blood 2009, 113, 4052-4062.
88. Stolzel, F.; Steudel, C.; Oelschlagel, U.; Mohr, B.; Koch, S.; Ehninger, G.; Thiede, C. Mechanisms of resistance against pkc412 in resistant flt3-itd positive human acute myeloid leukemia cells. Ann. Hematol. 2010, 89, 653-662.
89. Herrmann, M.D.; Lennerz, J.K.; Bullinger, L.; Bartholomae, S.; Holzmann, K.; Westhoff, M.A.; Corbacioglu, S.; Debatin, K.M. Transitory dasatinib-resistant states in kitmut t(8;21) acute myeloid leukemia cells correlate with altered kit expression. Exp. Hematol. 2014, 42, 90-100.
90. Saito, N.; Ishihara, S.; Kaneko, K. Baldwin effect under multipeaked fitness landscapes: Phenotypic fluctuation accelerates evolutionary rate. Phys. Rev. E 2013, 87, 052701.
91. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987-996.
92. Johnson, D.R.; O'Neill, B.P. Glioblastoma survival in the united states before and during the temozolomide era. J. Neurooncol. 2011, 107, 359-364.
93. Kim, M.; Lee, K.H.; Yoon, S.W.; Kim, B.S.; Chun, J.; Yi, H. Analytical tools and databases for metagenomics in the next-generation sequencing era. Genomics Inform. 2013, 11, 102-113.
94. Lee, S.H.; Sim, S.H.; Kim, J.Y.; Cha, S.; Song, A. Application of cancer genomics to solve unmet clinical needs. Genomics Inform. 2013, 11, 174-179.
95. Van Oostrum, J.; Calonder, C.; Rechsteiner, D.; Ehrat, M.; Mestan, J.; Fabbro, D.; Voshol, H. Tracing pathway activities with kinase inhibitors and reverse phase protein arrays. Proteomics Clin. Appl. 2009, 3, 412-422.
96. Carragher, N.O.; Unciti-Broceta, A.; Cameron, D.A. Advancing cancer drug discovery towards more agile development of targeted combination therapies. Future Med. Chem. 2012, 4, 87-105.
97. Huse, J.T.; Holland, E.C. Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 2010, 10, 319-331.
98. De Witt Hamer, P.C.; van Tilborg, A.A.; Eijk, P.P.; Sminia, P.; Troost, D.; van Noorden, C.J.; Ylstra, B.; Leenstra, S. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 2008, 27, 2091-2096.
99. Pollard, S.M.; Yoshikawa, K.; Clarke, I.D.; Danovi, D.; Stricker, S.; Russell, R.; Bayani, J.; Head, R.; Lee, M.; Bernstein, M.; et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4, 568-580.
100. Seyfried, T.N.; Marsh, J.; Shelton, L.M.; Huysentruyt, L.C.; Mukherjee, P. Is the restricted ketogenic diet a viable alternative to the standard of care for managing malignant brain cancer? Epilepsy Res. 2011, 100, 310-326.
101. Kast, R.E.; Boockvar, J.A.; Bruning, A.; Cappello, F.; Chang, W.W.; Cvek, B.; Dou, Q.P.; Duenas-Gonzalez, A.; Efferth, T.; Focosi, D.; et al. A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (cusp9) by the international initiative for accelerated improvement of glioblastoma care. Oncotarget 2013, 4, 502-530.
102. Amaravadi, R.K.; Thompson, C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin. Cancer Res. 2007, 13, 7271-7279.
103. Huang, Q.; Li, F.; Liu, X.; Li, W.; Shi, W.; Liu, F.F.; O'Sullivan, B.; He, Z.; Peng, Y.; Tan, A.C.; et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 2011, 17, 860-866.
104. Barbero, S.; Mielgo, A.; Torres, V.; Teitz, T.; Shields, D.J.; Mikolon, D.; Bogyo, M.; Barila, D.; Lahti, J.M.; Schlaepfer, D.; et al. Caspase-8 association with the focal adhesion complex promotes tumor cell migration and metastasis. Cancer Res. 2009, 69, 3755-3763.
105. Gdynia, G.; Grund, K.; Eckert, A.; Bock, B.C.; Funke, B.; Macher-Goeppinger, S.; Sieber, S.; Herold-Mende, C.; Wiestler, B.; Wiestler, O.D.; et al. Basal caspase activity promotes migration and invasiveness in glioblastoma cells. Mol. Cancer Res. 2007, 5, 1232-1240.
106. Sun, Y.; Campisi, J.; Higano, C.; Beer, T.M.; Porter, P.; Coleman, I.; True, L.; Nelson, P.S. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through wnt16b. Nat. Med. 2012, 18, 1359-1368.
107. Basu, S.; Rajakaruna, S.; Menko, A.S. Insulin-like growth factor receptor-1 and nuclear factor kappab are crucial survival signals that regulate caspase-3-mediated lens epithelial cell differentiation initiation. J. Biol. Chem. 2012, 287, 8384-8397.
108. Fernando, P.; Brunette, S.; Megeney, L.A. Neural stem cell differentiation is dependent upon endogenous caspase 3 activity. FASEB J. 2005, 19, 1671-1673.
109. Esserman, L.J.; Thompson, I.M., Jr.; Reid, B. Overdiagnosis and overtreatment in cancer: An opportunity for improvement. JAMA 2013, 310, 797-798.
110. Wen, P.Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med. 2008, 359, 492-507.